The North America Transcatheter Aortic Valve Replacement Market should witness market growth of 6.3% CAGR during the forecast period (2022-2028).
TheTAVR devices have higher safety-related benefits, according to several recently published studies. These studies also conclude a decreased incidence of paravalvular regurgitation, valve embolization, and other bleeding events when transcatheter heart valve devices are used. In addition, technology development is quite popular in the rapidly evolving transcatheter aortic valve replacement market.
This factor will encourage the growth of the transcatheter heart valve replacement market. Cardiovascular specialists at the forefront of healthcare who use ground-breaking research, cutting-edge technology, and transcatheter aortic valve replacement (TAVR) to treat some of the most complicated heart problems are in charge of numerous extensive initiatives. TAVR is a novel, quickly evolving therapy that provides patients with the best TAVR technology.
According to the CDC's data, heart diseaseremains the leading cause of mortality in the United States for men, women, and members of the majority of racial and ethnic groups. In the US, cardiovascular disease claims one life every 34 seconds. 1 in 5 deaths in the United States in 2020 was caused by heart disease, which claimed about 697,000 lives. Throughout 2017 and 2018, the cost of heart disease in the US was roughly $229 billion. Valvular heart disease affects 2.5% of Americans, but older persons are more likely to develop it. Valvular heart disease affects roughly 13% of those born before 1943.
The US market dominated the North America Transcatheter Aortic Valve Replacement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,129.3 million by 2028. The Canada market is poised to grow at a CAGR of 8.7% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 7.8% during (2022-2028).
Based on Material, the market is segmented into Nitinol, Stainless Steel, Cobalt-Chromium and Others. Based on Implantation Procedure, the market is segmented into Transfemoral, Transapical and Transaortic. Based on Mechanism, the market is segmented into Balloon-expanding Valve and Self-expanding Valve. Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
TheTAVR devices have higher safety-related benefits, according to several recently published studies. These studies also conclude a decreased incidence of paravalvular regurgitation, valve embolization, and other bleeding events when transcatheter heart valve devices are used. In addition, technology development is quite popular in the rapidly evolving transcatheter aortic valve replacement market.
This factor will encourage the growth of the transcatheter heart valve replacement market. Cardiovascular specialists at the forefront of healthcare who use ground-breaking research, cutting-edge technology, and transcatheter aortic valve replacement (TAVR) to treat some of the most complicated heart problems are in charge of numerous extensive initiatives. TAVR is a novel, quickly evolving therapy that provides patients with the best TAVR technology.
According to the CDC's data, heart diseaseremains the leading cause of mortality in the United States for men, women, and members of the majority of racial and ethnic groups. In the US, cardiovascular disease claims one life every 34 seconds. 1 in 5 deaths in the United States in 2020 was caused by heart disease, which claimed about 697,000 lives. Throughout 2017 and 2018, the cost of heart disease in the US was roughly $229 billion. Valvular heart disease affects 2.5% of Americans, but older persons are more likely to develop it. Valvular heart disease affects roughly 13% of those born before 1943.
The US market dominated the North America Transcatheter Aortic Valve Replacement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,129.3 million by 2028. The Canada market is poised to grow at a CAGR of 8.7% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 7.8% during (2022-2028).
Based on Material, the market is segmented into Nitinol, Stainless Steel, Cobalt-Chromium and Others. Based on Implantation Procedure, the market is segmented into Transfemoral, Transapical and Transaortic. Based on Mechanism, the market is segmented into Balloon-expanding Valve and Self-expanding Valve. Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
Scope of the Study
By Material
- Nitinol
- Stainless Steel
- Cobalt-Chromium
- Others
By Implantation Procedure
- Transfemoral
- Transapical
- Transaortic
By Mechanism
- Balloon-expanding Valve
- Self-expanding Valve
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- MicroPort Scientific Corporation
- LivaNova PLC
- TTK Healthcare Limited
- Meril Life Science Private Limited
- JenaValve Technology, Inc.
- Bracco S.p.A
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Transcatheter Aortic Valve Replacement Market, by Material
1.4.2 North America Transcatheter Aortic Valve Replacement Market, by Implantation Procedure
1.4.3 North America Transcatheter Aortic Valve Replacement Market, by Mechanism
1.4.4 North America Transcatheter Aortic Valve Replacement Market, by End-use
1.4.5 North America Transcatheter Aortic Valve Replacement Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Transcatheter Aortic Valve Replacement Market
Chapter 4. North America Transcatheter Aortic Valve Replacement Market by Material
4.1 North America Nitinol Market by Country
4.2 North America Stainless Steel Market by Country
4.3 North America Cobalt-Chromium Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Transcatheter Aortic Valve Replacement Market by Implantation Procedure
5.1 North America Transfemoral Market by Country
5.2 North America Transapical Market by Country
5.3 North America Transaortic Market by Country
Chapter 6. North America Transcatheter Aortic Valve Replacement Market by Mechanism
6.1 North America Balloon-expanding Valve Market by Country
6.2 North America Self-expanding Valve Market by Country
Chapter 7. North America Transcatheter Aortic Valve Replacement Market by End-use
7.1 North America Hospitals Market by Country
7.2 North America Ambulatory Surgical Centers Market by Country
7.3 North America Others Market by Country
Chapter 8. North America Transcatheter Aortic Valve Replacement Market by Country
8.1 US Transcatheter Aortic Valve Replacement Market
8.1.1 US Transcatheter Aortic Valve Replacement Market by Material
8.1.2 US Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.1.3 US Transcatheter Aortic Valve Replacement Market by Mechanism
8.1.4 US Transcatheter Aortic Valve Replacement Market by End-use
8.2 Canada Transcatheter Aortic Valve Replacement Market
8.2.1 Canada Transcatheter Aortic Valve Replacement Market by Material
8.2.2 Canada Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.3 Canada Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.4 Canada Transcatheter Aortic Valve Replacement Market by End-use
8.3 Mexico Transcatheter Aortic Valve Replacement Market
8.3.1 Mexico Transcatheter Aortic Valve Replacement Market by Material
8.3.2 Mexico Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.3 Mexico Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.4 Mexico Transcatheter Aortic Valve Replacement Market by End-use
8.4 Rest of North America Transcatheter Aortic Valve Replacement Market
8.4.1 Rest of North America Transcatheter Aortic Valve Replacement Market by Material
8.4.2 Rest of North America Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.3 Rest of North America Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.4 Rest of North America Transcatheter Aortic Valve Replacement Market by End-use
Chapter 9. Company Profiles
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Product Launches and Product Expansions:
9.1.5.2 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Medtronic PLC
9.2.1 Company overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Product Launches and Product Expansions:
9.2.5.2 Approvals and Trials:
9.2.6 SWOT Analysis
9.3 Boston Scientific Corporation
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Product Launches and Product Expansions:
9.3.5.2 Acquisition and Mergers:
9.3.5.3 Approvals and Trials:
9.4 Edwards Lifesciences Corporation
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Product Launches and Product Expansions:
9.5 MicroPort Scientific Corporation
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.6 LivaNova PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.7 TTK Healthcare Limited
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Meril Life Sciences Private Limited
9.8.1 Company Overview
9.9 JenaValve Technology, Inc.
9.9.1 Company Overview
9.10. Bracco S.p.A.
9.10.1 Company Overview
Companies Mentioned
- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- MicroPort Scientific Corporation
- LivaNova PLC
- TTK Healthcare Limited
- Meril Life Science Private Limited
- JenaValve Technology, Inc.
- Bracco S.p.A
Methodology
LOADING...
